While incretin drugs work nicely in a variety of metabolic disorders, many experts inside and outside the biopharma industry are exercised about one of their apparent drawbacks: the risk of loss of muscle tissue.
Rivus Gets A Muscle-Sparing Heart Failure Hit
But competing with the likes of Wegovy and Zepbound will be a big ask.
